Compositions and methods for reducing body fat

• US 9,795,614 B2
• Filed: 08/22/2016
• Issued: 10/24/2017
• Est. Priority Date: 03/23/2006
• Status: Active Grant

• Current Assignee: Topokine Therapeutics, Inc. (Abbvie Incorporated)
• Original Assignee: Topokine Therapeutics, Inc. (Abbvie Incorporated)
• Inventors: Grosskreutz, Cynthia L., Pasquale, Louis R., Singer, Michael S., Kalayoglu, Murat V.
• Primary Examiner(s): FAY, ZOHREH A
• Application Number:
  US15/243,641
• Publication Number:
  US 20160354386A1
• Time in Patent Office: 428 Days
• CPC Class Codes: A61K 31/5575 having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
• CPC Class Codes: A61K 8/37 Esters of carboxylic acids
• CPC Class Codes: A61K 8/42 Amides
• CPC Class Codes: A61K 8/69 containing fluorine
• CPC Class Codes: A61K 9/0014 Skin, i.e. galenical aspects of topical compositions non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61K 9/0021 Intradermal administration, e.g. through microneedle arrays, needleless injectors mechanical aspects A61M
• CPC Class Codes: A61K 9/0024 Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L
• CPC Class Codes: A61K 9/0048 Eye, e.g. artificial tears
• CPC Class Codes: A61P 3/04 Anorexiants; Antiobesity agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61Q 19/06 for countering cellulitis

Abstract

The present invention relates to compositions, such as bimatoprost, latanoprost and travoprost, and methods to reduce fat in the body of an individual, for example, by topical administration, injection, and/or implantation of such compositions.

Claims

1. A method for reducing orbital fat, the method comprising administering to an individual suffering from undesired orbital fat a therapeutically effective amount of latanoprost, or a pharmaceutically acceptable salt thereof.

2. The method of claim 1, wherein the latanoprost, or a pharmaceutically acceptable salt thereof, is administered to the skin of the individual'"'"'s face.

3. The method of claim 2, wherein the step of administering is by topical administration.

4. The method of claim 2, wherein the step of administering is by transdermal administration.

5. The method of claim 2, wherein the step of administering is by injection.

6. The method of claim 2, wherein the step of administering is by implanting an implantable depot of latanoprost, or a pharmaceutically acceptable salt thereof, into the skin.

7. The method of claim 1, wherein the method comprises administering a pharmaceutical composition containing latanoprost, or a pharmaceutically acceptable salt thereof, at a concentration ranging from about 0.001% to about 1.0% (w/v), inclusive.

8. The method of claim 1, wherein the method is performed as an adjunct to a cosmetic or surgical procedure.

9. The method of claim 8, wherein the cosmetic or surgical procedure is selected from the group consisting of rhinoplasty, botulinum toxin, orbital decompression, midface lift, sub-orbicularis oculi fat lift, and brow lift.

10. The method of claim 8, wherein the method is performed as an adjunct to a cosmetic or surgical procedure during the pre-operative period.

11. The method of claim 8, wherein the method is performed as an adjunct to a cosmetic or surgical procedure during the peri-operative period.

12. The method of claim 8, wherein the method is performed as an adjunct to a cosmetic or surgical procedure during the post-operative period.

13. The method of claim 1, wherein the individual suffers from thyroid orbitopathy.

14. The method of claim 1, wherein the individual suffers from prominent facial fat pads.

15. The method of claim 1, wherein the individual suffers from orbital fat prolapse.

16. The method of claim 1, wherein the reduction in the undesired orbital fat leads to an improvement of exophthalmos, eyelid displacement, ocular exposure, or optic neuropathy.

17. The method of claim 1, wherein the undesired orbital fat is a lipoma.

18. The method of claim 1, wherein latanoprost, or a pharmaceutically acceptable salt thereof, is administered to eye, orbital tissue, or orbital spaces.